{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000015","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.521940+00:00","generated_at":"2026-05-15T21:59:20.487911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M","bullets":["Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.","Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.","Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.","Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.","Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000015","json":"https://secwatch.observer/filing/0001087294-26-000015.json","markdown":"https://secwatch.observer/filing/0001087294-26-000015.md","text":"https://secwatch.observer/filing/0001087294-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/0001087294-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/cpix-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:59:20.487911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}